banter and General Discussion, page-10591

...& here's another & related thing that may (or may not) be of interest to you. I don't believe it's been remarked on by other posters on HC:MSB.

You'd have noticed in my post above ( Post #:75330533 ), that I underlined a section of the transcript where CEO Itescu talked at the 2023 AGM about corporate initiatives to 'strengthen our balance sheet' during the 12 months ending June 30, 2024.

Yet in the Financial Report in the most recent Quarterly Activities 4C (link here), CEO Itescu used slightly different terminology when advising the market of the financial forecast pending Ryoncil launch i.e.

" ...We continue to work on corporate and strategic initiatives to access commercial distribution channels and optimize our balance sheet."

To me there is a real financial & management accounting difference in this choice of words by the CEO. 'Optimize' is not 'Strengthen', when it comes to balance sheets - the Big 4 have entire divisions focussed on ranges of mechanisms available to optimize balance sheets. For example, with a biotech like MSB either royalty monetization or revenue interest financing would fit the 'optimize' description, IMO. Just for argument's sake, MSB could with JCR's agreement convert, say, the existing JCR Pharmaceuticals royalty to cash, or alternatively agree with a royalty aggregator to convert some of MSB's future income stream from Ryoncil revenue under what would effectively be a synthetic royalty.

And neither of these approaches is ordinarily dilutive of equity. Food for thought.

Let's see how the Board tackle the financial forecast for this pre- Ryoncil launch period in the activities update on August 28th.

Cheers all